General Discussions
Steroid use while cytokine release syndrome (CRS) and neurologic toxicities are at grade 1, instead of waiting until grade 3, reduces the rate of CAR T-cell treatment–related CRS and neurolog...
By Essie Roman, LMSW, Women's Clinic Program Coordinator, CancerCare Breast cancer is the second-most common cancer among American women, after skin cancer. Currently, the average risk of...
BLU-667, a next-generation tyrosine kinase inhibitor, appeared to be well-tolerated and had broad clinical benefit among patients with advanced, RET-altered solid tumors who progressed on prio...
Not all patients with advanced non–small cell lung cancer (NSCLC) are recommended for genomic testing when treated in a community setting, and are therefore not being appropriately tested for...
Oncology nurses should aspire to give care that goes above and beyond what is necessary to assure the safety and wellbeing of their patients. They are charged with reducing the suffering of patient...
By: Charlotte Ference, LMSW The American Cancer Society estimates that 5%-10% of cancers are connected with mutations in the DNA that are inherited through generations.1 For millions of patie...
Stacie Dusetzina, PhD Studies show that cost is a factor in patient adherence to their oral anticancer medications, but the financial burden of oral chemotherapy drugs is projected to still be to...
The FDA has approved the PI3K inhibitor alpelisib (Piqray) for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast ca...
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.